



## EVENING PRIMROSE OIL

### What is it?

Evening primrose oil is made from the seeds of *Oenothera biennis* or evening primrose. This plant is a tall biennial that is native to North America. Evening primrose oil is rich in a substance called gamma-linolenic acid (GLA), which contributes to many important functions in the body. GLA is normally created during the breakdown of omega-6 fatty acids inside the body. Omega-3 and omega-6 fatty acids are essential fatty acids. They are called essential because they must be included in the diet since our body can't make them. In theory, chronic viral infections, such as HIV, may impair the body's ability to convert omega-6 fatty acids into GLA. Evening primrose oil may, therefore, be useful to ensure adequate levels of GLA in the body. It may have other uses as well.

### What do people with HIV use this supplement for?

#### 1. To help heal nerve damage (peripheral neuropathy)

Peripheral neuropathy (PN) is a burning or tingling in the hands and feet. It is associated with the use of the anti-HIV drugs ddI, d4T and ddC. PN also occurs in people with diabetes. Several trials have shown that evening primrose oil can help relieve the symptoms of diabetic PN. In one study, 22 people who took four grams of evening primrose oil daily for six months had a significant improvement in symptoms. Evening primrose oil appears to be more effective for

this purpose than other oils containing GLA such as borage or black currant oil. Evening primrose oil has not been studied as a treatment for peripheral neuropathy in people with HIV. Nevertheless, nutritionists like Lark Lands recommend GLA supplements in combination with B-complex vitamins, vitamin E and omega-3 fatty acid supplements for PHAs suffering from neuropathy.

#### 2. To treat skin conditions associated with anti-HIV drugs

Some anti-HIV drugs can cause dry skin and itching, symptoms most commonly associated with indinavir (Crixivan). Electronic forums such as PI-treat and Crix-list contain anecdotal reports that describe improvements in these symptoms with the use of evening primrose oil. According to such anecdotes, two grams a day is generally recommended. Evening primrose oil is also used to treat eczema and dermatitis in HIV-negative people. Although some studies have not shown an improvement, an analysis of nine different trials showed that evening primrose oil significantly improved dermatitis. The improvements continued over time and were greater when higher doses were used. Evening primrose oil was, however, less successful at relieving the itch caused by this condition.

#### 3. To cope with premenstrual syndrome

Compared with women not infected with HIV, many HIV-positive women have heavier periods and more intense symptoms of premenstrual syndrome, such as pain and bloating. Evening



primrose oil is commonly used in Britain to treat these symptoms. Naturopaths generally suggest four to six months of use in order for symptoms to improve.

#### 4. To reduce cholesterol levels

In recent years, many PHAs have experienced elevated levels of cholesterol that may be linked to the use of anti-HIV drugs, particularly protease inhibitors. Evening primrose has helped decrease cholesterol in HIV-negative people. One British study using three to four grams of evening primrose oil for 12 weeks showed significant benefit. Both men and women participated in the study. The treatment was most effective in those participants with the most abnormal cholesterol levels. In the subjects with the highest cholesterol levels at the start of the study, total cholesterol levels decreased by 30 per cent. The potential of evening primrose oil to reduce cholesterol levels in PHAs taking protease inhibitors has not been studied.

## Available forms and usage

Evening primrose oil is usually sold in capsules or as a liquid. It should contain a minimum of eight per cent gamma-linolenic acid. PHAs usually take two grams a day with food, divided into several doses. People experiencing peripheral neuropathy may take doses as high as four grams. To prevent the oxidation of evening primrose oil, at least 400 IU/day of vitamin E should also be taken with meals. Evening primrose oil is now widely available and can be purchased from herbalists or from health food or drug stores.

## Cautions and concerns

Evening primrose oil is generally considered quite safe. Rare adverse effects include nausea, headache and diarrhea.

Evening primrose oil may have an effect on the immune system but these results have been inconclusive and sometimes contradictory. Some nutritionists recommend that PHAs take evening primrose oil (omega-6) in combination with an

omega-3 fatty acid like flaxseed oil in order to balance their intake of essential fatty acids.

Evening primrose should not be taken by people with mental illness who experience mania because it may make this condition worse. People with epilepsy or other people who experience seizures should take it cautiously because it has been associated with an increased frequency of seizures in a few cases.

Evening primrose oil should be used cautiously by people taking drugs that reduce blood clotting, such as aspirin. In theory, evening primrose oil may be less effective in people taking beta-blockers, which are drugs used to treat high blood pressure.

## Credits

Author: Lori Lyons

Created: April 2002

Design: Renata Lipovitch

## References

- Boon H, Smith M. *The Botanical Pharmacy*. Kingston: Quarry Health Books, 1999.
- Horrobin DF, Manku MS. How do polyunsaturated fatty acids lower plasma cholesterol levels. *Lipids* 1983;18:558-62.
- Lands Lark. Nutrient therapy for neuropathy, 1999. Available at: <http://www.aids.org/daair/>
- Morse PF, Horrobin DF et al. Meta-analysis of placebo-controlled studies of the efficacy of Epoprostenol on the treatment of atopic eczema. *British Journal of Dermatology* 1989;121:75-90.
- Nemecz G. Evening Primrose. *US Pharmacist* 1998 Nov. Available at: <http://www.uspharmacist.com/>
- Puolakka J, Makarainen L et al. Biochemical and clinical effects of treating the premenstrual syndrome with prostaglandin synthesis precursors. *Journal of Reproductive Medicine* 1985 Mar;30(3):149-53.



## Disclaimer

**Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV-related illness and the treatments in question.**

The Canadian AIDS Treatment Information Exchange (CATIE) in good faith provides information resources to help people living with HIV/AIDS who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

We do not guarantee the accuracy or completeness of any information accessed through or published or provided by CATIE. Users relying on this information do so entirely at their own risk. Neither CATIE nor Health Canada nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. The views expressed herein or in any article or publication accessed or published or provided by CATIE are solely those of the authors and do not reflect the policies or opinions of CATIE or the official policy of the Minister of Health Canada.

## Permission to reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: *This information was provided by the Canadian AIDS Treatment Information Exchange (CATIE). For more information, contact CATIE at 1.800.263.1638.*

## Contact CATIE

**by telephone**

1.800.263.1638

416.203.7122

**by fax**

416.203.8284

**by e-mail**

info@catie.ca

**on the Web**

<http://www.catie.ca>

**by mail**

505-555 Richmond Street West

Box 1104

Toronto, Ontario

M5V 3B1

Canada



Funding has been provided by Health Canada, under the Canadian Strategy on HIV/AIDS.

